|Tumor||Author||Year||Method||No. of Patients||Title||Journal||Abstract Link|
|Soft Tissue Sarcoma||Lindner||2021||HT||#||Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas||Eur J Cancer|
|Soft Tissue Sarcoma||Issels||2021||CT+HT||109||Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial||Eur J Cancer|
|Soft Tissue Sarcoma||Issels||2020||HT||109||Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – a case report||Int J Hyperthermia|
|Soft Tissue Sarcoma||Bücklein||2020||ICE+HT||110||Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma||Sarcoma|
|Soft Tissue Sarcoma||Aklan||2019||HT||#||Regional deep hyperthermia: quantitative evaluation of predicted and direct measured temperature distributions in patients with high-risk extremity soft-tissue sarcoma||Int J Hyperthermia|
|Soft Tissue Sarcoma||Zschaeck||2018||CT+HT||61||Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison||Int J Hyperthermia|
|Soft Tissue Sarcoma||Issels||2018||CT vs.
|341||Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.||JAMA|
|Soft Tissue Sarcoma||Eckert||2017||CT+HT||42||Radiotherapy and hyperthermia with curative intent in recurrent high risk soft tissue sarcomas||Int J Hyperthermia|
|Soft Tissue Sarcoma||Angele||2014||CT vs.
|341||Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study.||Ann Surg Oncol|
|Soft Tissue Sarcoma||Issels||2010||CT vs.
|341||Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.||Lancet|
|Soft Tissue Sarcoma||Schlemmer||2010||RCT+HT||47||Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS)||Int J Hyperthermia|
|Soft Tissue Sarcoma||Fiegl||2004||CT+HT||20||Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.||Int J Hyperthermia|
|Soft Tissue Sarcoma||Wendtner||2002||CT+HT||58||Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.||JCO|
|Soft Tissue Sarcoma||Issels||2001||CT+HT||59||Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.||Eur J Cancer|
|Soft Tissue Sarcoma||Wendtner||2001||RCT+HT||54||Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.||Eur J Cancer|
|Soft Tissue Sarcoma||Prosnitz||1999||RT+HT||97||The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy.||IJRO|
|Soft Tissue Sarcoma||Scully||1994||RT+HT||40||Clinical outcome after neoadjuvant thermoradiotherapy in high grade soft tissue sarcomas||J Surg Oncol|
|Soft Tissue Sarcoma||Issels||1990||CT+HT||40||Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.||JCO|
RT-Radiotherapy; HT-Hyperthermia; LHT-Local Hyperthermia; CHT-Chemothyperthermia; CTX-Chemotherapy; MMC-Mitomycin C; EHT; Endocavity Hyperthermia; IHT-Interstitial Hyperthermia; HIPEC-Heated Intraperitoneal Chemotherapy; RCT-RadioChemotherapy; BCG-Bacillus Calmette-Guerin; CRT-Conformal Radiotherapy